CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 147 enrolled
Drug / intervention
Rifaximin +1 moredrug
Likely dose
Rifaximin 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00858988
NCT00858988N/ACompleted
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled Trial of Rifaximin, a Non-absorbable Antibiotic, in the Treatment of Tropical Enteropathy

Washington University School of Medicine·interventional·Posted Mar 10, 2009·Updated Nov 12, 2019

In Brief

A clinical study evaluating Rifaximin and Placebo for Tropical Enteropathy. Completed, enrolled 147 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether rifaximin is effective in the treatment of tropical enteropathy in a population of African children at high risk for this disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTropical Enteropathy
CountriesMalawi
CollaboratorsBaylor College of Medicine, Kamuzu University of Health Sciences, United States Department of Agriculture (USDA)

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 10, 2009
Enrollment StartSep 1, 2007
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.3 years ago

Interventions

Rifaximindrug

100mg of rifaxin for 7 consecutive days, twice daily

Placebodrug

twice daily for 7 consecutive days